Implications of the clinical predictive profile of peripheral sensorial neuropathy induced by oxaliplatin for nursing care in cancer of gastrointestinal topography: descriptive observational study
DOI:
https://doi.org/10.33448/rsd-v9i11.10594Keywords:
Colorectal câncer; Oncology Nursing; Chemotherapy; Toxicity.Abstract
Oxaliplatin is a medication used in the treatment of cancer patients, mainly with metastatic rectal colon cancer. However, it can promote the development of Peripheral Sensory Neuropathy (PSN). The objective of this study is to describe the profile of the clinical predictiveness of the development of NSP in patients exposed to Oxaliplatin, to support the safe practice of nursing care in this toxicity. The research was carried out between the months of August 2019 and March 2020, with 29 patients undergoing outpatient chemotherapy treatment at the Adult Chemotherapy Center of Unit I of the National Cancer Institute José Alencar Gomes da Silva, who used Oxaliplatin to treat neoplasia in the topography of the gastrointestinal tract, under the CAPOX and FOLFOX protocols, aged 18 years or over. The prevalence of clinical predictive factors was verified in decreasing order, point to type II diabetes, alcoholism and obesity. The profile of patients who have greater predictive characteristics of the development of PSN induced by Oxaliplatin is female, aged over 60 years and as important as the presentation of comorbidities is the cumulative dose to which they are exposed, sufficient to present neuropathic manifestations in medium dose 780 mg / m². The recognition of predictive factors, the use of instruments to measure the degree of severity of Neuropathy and the description of acute and chronic events can provide support for the management of Oxaliplatin toxicity.
References
Abdel-Rahman, O. (2019). Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies. Clinical and Translational Oncology, 21(4), 512-518. Recuperado de https://dx.doi.org/10.1007/s12094-018-1939-8
Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2011). Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database of Systematic Reviews, 31(3), CD005228. Recuperado de https://dx.doi.org/10.1002/14651858.CD005228.pub4.
Alejandro, L., Behrendt, C. E., Chen, K., Openshaw, H., & Shibata, S. (2013). Predicting acute and persistent neuropathy associated with oxaliplatin. American Journal of Clinical Oncology, 36(4), 331-336. Recuperado de https://dx.doi.org/10.1097/COC.0b013e318246b50 d.
Agência Nacional de Vigilância Sanitária-ANVISA. (2004). Resolução-RDC nº 220, de 21 de setembro de 2004. Brasília: ANVISA.
Bano, N., & Ikram, R. (2019). Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens. Pakistan Journal of Pharmaceutical Sciences, 32(1), 249-253.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 68(6), 394-424. Recuperado de https://dx.doi.org/10.3322/caac.21492.
Cassinello, J., Serrano, C., & De Mon, M. A. (2017). Clinical and neurophysiologic prospective study with time-event and long-term analysis of the chronic neurotoxicity associated with oxaliplatin in patients with colorectal cancer (CRC). Journal of Clinical Oncology, 35(15), e15150-e15150.
Conselho Federal de Enfermagem – COFEN. Resolução COFEN-210/1998. 1998. Acesso em 10 de agosto de 2020, em http://www.cofen.gov.br/resoluo-cofen-2101998_4257.html.
Costa, T. C., Lopes, M., Anjos, A. C. Y., & Zago, M. M. F. (2015). Neuropatia periférica induzida pela quimioterapia: Revisão Integrativa da Literatura. Revista da Escola de Enfermagem, 49(2), 335-345. Recuperado de http://dx.doi.org/10.1590/S0080-623420150000200020.
Ferreira, R. S. (2017). Neuropatia sensorial periférica induzida pela cisplatina: estudo dos mecanismos de neurotoxicidade da cisplatina e do efeito protetor do éster fenetil do ácido cafeico (CAPE) em células PC12. Tese. Universidade de São Paulo, São Paulo. Acesso em 10 de agosto de 2020, em http://www.teses.usp.br/teses/disponiveis/60/60134/tde-17102018-104638/
Freitas, M. S. H. S., & Fuly, P. dos S. C. (2020). Nursing Care in the management of hipersensitivity reaction in patients undergoing antineoplastic therapy: review for clinical practice. Research, Society and Developement, 9(7), e442974263. Recuperado de https://doi.org/10.33448/rsd-v9i7.4263.
Hsu, S. Y., Huang, W. S., Lee SH, Chu, T. P., Lin, Y. C., Lu, C. H., & Beaton, R. D. (2019). Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin‐induced peripheral neuropathy in Taiwanese patients with colorectal cancer. European Journal of Cancer Care, 28(2), e12976. Recuperado de https://doi.org/10.1111/ecc.12976
Instituto Nacional de Câncer-INCA. (2020). Estatísticas de câncer. Brasília: Ministério da saúde. Acesso em 8 de outubro de 2020, em https://www.inca.gov.br/numeros-de-cancer.
Instituto Nacional de Câncer José Alencar Gomes da Silva. INCA. (2019). Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: INCA. Acesso em 8 de outubro de 2020, em https://www.inca.gov.br/publicacoes/livros/estimativa-2020-incidencia-de-cancer-no-brasil
Kumar, V., Abbas, A., & Aster, J. C. (2013). Robbins Patologia Básica. 9. ed. Rio de Janeiro: Elsevier.
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, M., & Arnold, D. (2013). ESMO Guidelines Working Group. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24(suppl 6), vi64-vi72. Recuperado de https://doi.org/10.1093/annonc/mdt354.
Messersmith, W. A. (2017). Systemic Management of Colorectal Cancer. Journal of the National Comprehensive Cancer Network, 15(5S), 699-702. Recuperado de https://doi.org/10.6004/jnccn.2017.0077
National Comprehensive Cancer Network – NCCN. (2019). Guidelines for Patients: Colon Cancer. Acesso em 8 de outubro de 2020, em https://www.nccn.org/patients/guidelines/colon/ index.html.
NCI. Common Terminology Criteria for Adverse Events (CTCAE). (2017). Acesso em 8 de outubro de 2020, em https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
Organização Mundial da Saúde-OMS. (2019). Uso nocivo de álcool mata mais de 3 milhões de pessoas a cada ano; homens são a maioria. Acesso em 15 de outubro de 2020, em https://www.paho.org/bra/index.php?option=com_content&view=article&id=5763:uso-nocivo-de-alcool-mata-mais-de-3-milhoes-de-pessoas-a-cada-ano-homens-sao-a-maioria&Itemid=839.
Ottaiano, A., Nappi, A., Tafuto, S., Nasti, G., Divitiis, C., Romano, C., Cassata, A. et al. (2016). Diabetes and body mass index are associated with neuropathy and prognosis in colon cancer patients treated with capecitabine and oxaliplatin adjuvant chemotherapy. Oncology, 90(1), 36-42. Recuperado de https://doi.org/10.1159/000442527.
Palugulla, S., Thakkar, D. N., Kayal, S., Narayan, S. K., & Dkhar, S. A. (2017). Association of voltage-gated sodium channel genetic polymorphisms with oxaliplatin-induced chronic peripheral neuropathy in south indian cancer patients. Asian Pacific Journal of Cancer Prevention, 18(11), 3157–3165. Recuperado de https://doi.org/10.22034/APJCP.2017.18.11.3157.
Raphael, M. J.; Fischer, H. D., & Fung, K. (2017). Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer. Clinical Colorectal Cancer, 16(4), 397-404. Recuperado de https://doi.org/10.1016/j.clcc.2017.03.013.
Sanofi-Aventis Farmacêutica Ltda. (2015). Eloxatin® (oxaliplatin). Acesso em 15 de outubro de 2020, em http://products .sanofi.us/eloxatin/eloxatin.pdf.
Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer Statistics. CA: A Cancer Journal for Clinicians, 70(1), 7-30. Recuperado de https://doi.org/10.3322/caac.21590.
Soares, R. L., de Oliveira Ribeiro, S. M., de Backer Fachin, L., de Souza Lima, A. C. T., de Oliveira Ramos, L., & Ferreira, L. V. (2017). Avaliação de rotina do pé diabético em pacientes internados–prevalência de neuropatia e vasculopatia. HU Revista, 43(3), 205-210. Recuperado de https://doi.org/10.34019/1982-8047.2017.v43.2746.
Tanishima, H., Tominaga, T., Kimura, M., Maeda, T., Shirai, Y., & Horiuchi, T. (2017). Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy. Supportive Care in Cancer, 25(5), 1383-1389. Recuperado de https://doi.org/10.1007/s00520-016-3514-6.
Uwah, A. N.; Ackler, J.; Leighton, Jr. J. C.; Pomerantz, S. & Tester, W. (2012). The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clinical Colorectal Cancer, 11(4), 275-279. Recuperado de https://doi.org/10.1016/j.clcc.2012.05.002.
Velasco, R., Bruna, J., Briani, C., Argyriou, A. A., Cavaletti, G., Alberti, P., Frigeni, B., et al. (2014). Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. Journal of Neurology, Neurosurgery, and Psychiatry, 85(4), 392-398. Recuperado de https://doi.org/10.1136/jnnp-2013-305334.
Vincenzi, B., Frezza, A. M., Schiavon, G., Spoto, C., Silvestris, N., Addeo, R., Catalano, V. et al. (2013). Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Supportive Care in Cancer, 21(5), 1313-1319. Recuperado de https://doi.org/10.1007/s00520-012-1667-5.
Wang, X. S., Shi, Q., Dougherty, P. M., Mendoza, T. R., Williams, L. A., Fogelman, D. R., & Cleeland, C. S. (2016). Prechemotherapy touch sensation deficits predict oxaliplatin-induced neuropathy in patients with colorectal cancer. Oncology, 90(3), 127-135. Recuperado de https://doi.org/10.1159/000443377.
Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., & Saito, Y. (2018). Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal. Cancer International Journal of Clinical Oncology, 23(1), 1-34. Recuperado de https://doi.org/10.1007/s10147-017-1101-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Lívia Márcia Vidal Pires; Patrícia dos Santos Claro Fuly
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
